End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 02 | Transcript : Altimmune, Inc. - Special Call | |
Mar. 27 | Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B | MT |
Financials (USD)
Sales 2024 * | 35.71M | Sales 2025 * | 28.57M | Capitalization | 515M |
---|---|---|---|---|---|
Net income 2024 * | -61M | Net income 2025 * | -147M | EV / Sales 2024 * | 11.8 x |
Net cash position 2024 * | 91.94M | Net cash position 2025 * | 285M | EV / Sales 2025 * | 8.05 x |
P/E ratio 2024 * |
-7.79
x | P/E ratio 2025 * |
-5.21
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.22% |
Latest transcript on Altimmune Inc
Managers | Title | Age | Since |
---|---|---|---|
Vipin K. Garg
CEO | Chief Executive Officer | 67 | 18-11-29 |
Director of Finance/CFO | 66 | 21-12-30 | |
Anthony Blandin
CMP | Compliance Officer | - | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchel Sayare
CHM | Chairman | 76 | 10-03-31 |
Mack Gill
BRD | Director/Board Member | 72 | 04-07-31 |
Philip Hodges
BRD | Director/Board Member | 56 | 03-08-31 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |